Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S M Seiler

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Thrombosis Research|April 15, 1994
2-[3-[2-(4,5-diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): 2). Oral activity and efficacy in animal models of arterial thrombosisS M Seiler, J O Buchanan, W A Schumacher, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|March 1, 1993
Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor productionM C Kowala, C E Mazzucco, K S Hartl, et al.
Regulatory Peptides|March 19, 1993
Binding and signal transduction of the cloned vascular angiotensin II (AT1a) receptor cDNA stably expressed in Chinese hamster ovary cellsM L Webb, H Monshizadegan, K E Dickinson, et al.
Thrombosis Research|April 15, 1994
2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of actionS M Seiler, C L Brassard, M E Federici, et al.
Journal of Medicinal Chemistry|January 22, 1993
Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H seriesN Balasubramanian, D R St Laurent, M E Federici, et al.
Thrombosis Research|November 1, 1989
Pharmacology of a potent, new antithrombotic agent, 1,3-dihydro-7,8-dimethyl-2H-imidazo[4,5-b]quinolin-2-one (BMY-20844)J O Buchanan, J S Fleming, B T Cornish, et al.
Bioorganic & Medicinal Chemistry|August 1, 1995
Active site-directed thrombin inhibitors--II. Studies related to arginine/guanidine bioisosteresD R St Laurent, N Balasubramanian, W T Han, et al.
Journal of Medicinal Chemistry|January 24, 1992
Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimeticN A Meanwell, M J Rosenfeld, J J Wright, et al.
The American Journal of Cardiology|December 1, 1989
Natural history of potentially lethal ventricular arrhythmias in patients treated with long-term antiarrhythmic drug therapyH L Kennedy, M K Sprague, S M Homan, et al.
Journal of Medicinal Chemistry|November 21, 1998
1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptaseK D Combrink, H B Gülgeze, N A Meanwell, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Thrombosis Research|April 15, 1994
2-[3-[2-(4,5-diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): 2). Oral activity and efficacy in animal models of arterial thrombosisS M Seiler, J O Buchanan, W A Schumacher, et al.
Arteriosclerosis and Thrombosis : a Journal of Vascular Biology|March 1, 1993
Prostacyclin agonists reduce early atherosclerosis in hyperlipidemic hamsters. Octimibate and BMY 42393 suppress monocyte chemotaxis, macrophage cholesteryl ester accumulation, scavenger receptor activity, and tumor necrosis factor productionM C Kowala, C E Mazzucco, K S Hartl, et al.
Regulatory Peptides|March 19, 1993
Binding and signal transduction of the cloned vascular angiotensin II (AT1a) receptor cDNA stably expressed in Chinese hamster ovary cellsM L Webb, H Monshizadegan, K E Dickinson, et al.
Thrombosis Research|April 15, 1994
2-[3-[2-(4,5-Diphenyl-2-oxazolyl) ethyl] phenoxy] acetic acid (BMY 42393): a new, structurally-novel prostacyclin partial agonist: 1). Inhibition of platelet aggregation and mechanism of actionS M Seiler, C L Brassard, M E Federici, et al.
Journal of Medicinal Chemistry|January 22, 1993
Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H seriesN Balasubramanian, D R St Laurent, M E Federici, et al.
Thrombosis Research|November 1, 1989
Pharmacology of a potent, new antithrombotic agent, 1,3-dihydro-7,8-dimethyl-2H-imidazo[4,5-b]quinolin-2-one (BMY-20844)J O Buchanan, J S Fleming, B T Cornish, et al.
Bioorganic & Medicinal Chemistry|August 1, 1995
Active site-directed thrombin inhibitors--II. Studies related to arginine/guanidine bioisosteresD R St Laurent, N Balasubramanian, W T Han, et al.
Journal of Medicinal Chemistry|January 24, 1992
Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimeticN A Meanwell, M J Rosenfeld, J J Wright, et al.
The American Journal of Cardiology|December 1, 1989
Natural history of potentially lethal ventricular arrhythmias in patients treated with long-term antiarrhythmic drug therapyH L Kennedy, M K Sprague, S M Homan, et al.
Journal of Medicinal Chemistry|November 21, 1998
1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptaseK D Combrink, H B Gülgeze, N A Meanwell, et al.
Pageof 4